Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 11/20 | 0.55 |
| ▸ | GRM5 | P41594 | 11/20 | 0.55 |
| ▸ | WNT3A | P56704 | 1/20 | 0.52 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.50 |
| ▸ | CNR1 | P21554 | 2/20 | 0.48 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.45 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1749492 | 1.00 | GRM1 (0.55) | GRM1GRM5WNT3APDK4CNR1 | |
| SCHEMBL18741854 | 0.88 | MEN1 (0.43) | GRM1GRM5WNT3APDK4CNR1 | |
| SCHEMBL30463486 | 0.88 | MEN1 (0.43) | GRM1GRM5WNT3APDK4CNR1 | |
| SCHEMBL903903 | 0.87 | GRM1 (0.56) | GRM1GRM5WNT3APDK4NAMPT | |
| SCHEMBL31039781 | 0.86 | GRM1 (0.55) | GRM1GRM5WNT3APDK4NAMPT | |
| SCHEMBL976835 | 0.86 | GRM1 (0.55) | GRM1GRM5WNT3APDK4NAMPT | |
| SCHEMBL29746802 | 0.86 | GRM1 (0.55) | GRM1GRM5WNT3APDK4NAMPT | |
| SCHEMBL13096687 | 0.86 | GRM1 (0.55) | GRM1GRM5WNT3APDK4NAMPT | |
| SCHEMBL30198712 | 0.86 | GRM1 (0.55) | GRM1GRM5WNT3APDK4NAMPT | |
| SCHEMBL20266499 | 0.86 | GRM1 (0.64) | GRM1GRM5WNT3APDK4NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250057852-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION | 2025-02-20 | — | — | US | disclosed |
| US-12083124-B2 | Bicyclic heterocycles as FGFR inhibitors | INCYTE CORPORATION (US) | 2024-09-10 | — | — | US | disclosed |
| US-20230338389-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION | 2023-10-26 | — | — | US | disclosed |
| US-11607416-B2 | Bicyclic heterocycles as FGFR inhibitors | INCYTE CORPORATION (US) | 2023-03-21 | — | — | US | disclosed |
| CN-115335376-A | Degradation of Bruton's Tyrosine Kinase (BTK) by conjugation of BTK inhibitor with E3 ligase ligand and methods of use thereof | 百济神州有限公司 | 2022-11-11 | — | — | CN | disclosed |
| EP-4045151-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | Incyte Corporation (US) | 2022-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12083124-B2 | Bicyclic heterocycles as FGFR inhibitors | FGFR1, FGFR3, FGFR2 | GRM1 2117/4885GRM5 1935/4885WNT3A 2837/4885 |
| US-20250057852-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | FGFR1, FGFR3, FGFR2 | GRM1 2117/4885GRM5 1935/4885WNT3A 2837/4885 |
| US-11607416-B2 | Bicyclic heterocycles as FGFR inhibitors | FGFR1, FGFR3, FGFR2 | GRM1 2117/4885GRM5 1935/4885WNT3A 2837/4885 |
| US-20230338389-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | FGFR1, FGFR3, FGFR2 | GRM1 2117/4885GRM5 1935/4885WNT3A 2837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.